- Zacks•9 days ago
As of late, it has definitely been a great time to be an investor in Achaogen, Inc. (AKAO).
- GlobeNewswire•14 days ago
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2017-- Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced ...
- TheStreet.com•14 days ago
Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.
AKAO : Summary for Achaogen, Inc. - Yahoo Finance
Achaogen, Inc. (AKAO)
NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
|Bid||17.30 x 2300|
|Ask||18.93 x 100|
|Day's Range||16.77 - 17.93|
|52 Week Range||2.59 - 18.26|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-7.12|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|